drugset / Trial / NCT00848640
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-12
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | — |